Logo image of CUE

CUE BIOPHARMA INC (CUE) Stock Fundamental Analysis

USA - NASDAQ:CUE - US22978P1066 - Common Stock

0.7676 USD
+0.07 (+9.75%)
Last: 10/31/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, CUE scores 2 out of 10 in our fundamental rating. CUE was compared to 534 industry peers in the Biotechnology industry. CUE has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CUE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CUE had negative earnings in the past year.
In the past year CUE has reported a negative cash flow from operations.
In the past 5 years CUE always reported negative net income.
CUE had a negative operating cash flow in each of the past 5 years.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -95.55%, CUE is not doing good in the industry: 74.72% of the companies in the same industry are doing better.
With a Return On Equity value of -214.19%, CUE is not doing good in the industry: 67.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -95.55%
ROE -214.19%
ROIC N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

CUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CUE has been increased compared to 1 year ago.
Compared to 5 years ago, CUE has more shares outstanding
The debt/assets ratio for CUE is higher compared to a year ago.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.56, we must say that CUE is in the distress zone and has some risk of bankruptcy.
CUE has a worse Altman-Z score (-13.56) than 78.84% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CUE is not too dependend on debt financing.
The Debt to Equity ratio of CUE (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -13.56
ROIC/WACCN/A
WACC8.73%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

CUE has a Current Ratio of 1.60. This is a normal value and indicates that CUE is financially healthy and should not expect problems in meeting its short term obligations.
CUE's Current ratio of 1.60 is on the low side compared to the rest of the industry. CUE is outperformed by 80.34% of its industry peers.
A Quick Ratio of 1.60 indicates that CUE should not have too much problems paying its short term obligations.
CUE has a Quick ratio of 1.60. This is in the lower half of the industry: CUE underperforms 79.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.86% over the past year.
CUE shows a decrease in Revenue. In the last year, the revenue decreased by -0.11%.
CUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.83% yearly.
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
Revenue 1Y (TTM)-0.11%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%11.14%

3.2 Future

The Earnings Per Share is expected to grow by 32.70% on average over the next years. This is a very strong growth
CUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 74.48% yearly.
EPS Next Y42.09%
EPS Next 2Y18.45%
EPS Next 3Y9.88%
EPS Next 5Y32.7%
Revenue Next Year-21.59%
Revenue Next 2Y-15.91%
Revenue Next 3Y4.54%
Revenue Next 5Y74.48%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.45%
EPS Next 3Y9.88%

More info and screens

0

5. Dividend

5.1 Amount

CUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUE BIOPHARMA INC

NASDAQ:CUE (10/31/2025, 8:00:01 PM)

0.7676

+0.07 (+9.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners22.62%
Inst Owner Change-0.09%
Ins Owners0.33%
Ins Owner Change0%
Market Cap58.99M
Revenue(TTM)8.29M
Net Income(TTM)-38895000
Analysts82.86
Price Target4.08 (431.53%)
Short Float %0.45%
Short Ratio1.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.29%
Min EPS beat(2)-9.77%
Max EPS beat(2)36.35%
EPS beat(4)3
Avg EPS beat(4)14.16%
Min EPS beat(4)-9.77%
Max EPS beat(4)36.35%
EPS beat(8)6
Avg EPS beat(8)15.81%
EPS beat(12)9
Avg EPS beat(12)10.93%
EPS beat(16)11
Avg EPS beat(16)10.9%
Revenue beat(2)1
Avg Revenue beat(2)-22.5%
Min Revenue beat(2)-67.11%
Max Revenue beat(2)22.12%
Revenue beat(4)2
Avg Revenue beat(4)16.02%
Min Revenue beat(4)-67.11%
Max Revenue beat(4)117.33%
Revenue beat(8)6
Avg Revenue beat(8)38.37%
Revenue beat(12)8
Avg Revenue beat(12)18.85%
Revenue beat(16)10
Avg Revenue beat(16)16.5%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.21%
EPS NY rev (1m)-3.61%
EPS NY rev (3m)27.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.12
P/FCF N/A
P/OCF N/A
P/B 3.25
P/tB 3.25
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.11
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -95.55%
ROE -214.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.61%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z -13.56
F-Score5
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)11.7%
Cap/Depr(5y)32.79%
Cap/Sales(3y)4.77%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
EPS Next Y42.09%
EPS Next 2Y18.45%
EPS Next 3Y9.88%
EPS Next 5Y32.7%
Revenue 1Y (TTM)-0.11%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%11.14%
Revenue Next Year-21.59%
Revenue Next 2Y-15.91%
Revenue Next 3Y4.54%
Revenue Next 5Y74.48%
EBIT growth 1Y18.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.07%
OCF growth 3YN/A
OCF growth 5YN/A

CUE BIOPHARMA INC / CUE FAQ

What is the fundamental rating for CUE stock?

ChartMill assigns a fundamental rating of 2 / 10 to CUE.


What is the valuation status of CUE BIOPHARMA INC (CUE) stock?

ChartMill assigns a valuation rating of 0 / 10 to CUE BIOPHARMA INC (CUE). This can be considered as Overvalued.


What is the profitability of CUE stock?

CUE BIOPHARMA INC (CUE) has a profitability rating of 0 / 10.


Can you provide the financial health for CUE stock?

The financial health rating of CUE BIOPHARMA INC (CUE) is 2 / 10.